Researchers find novel mechanism of resistance to anti-cancer drugs
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.
Funding Opportunity – Ovarian cancer-related projects
The Vanderbilt-Ingram Cancer Center (VICC) announces a funding opportunity to catalyze innovative, collaborative, ovarian cancer-related projects. The goal of this award is to provide funding for generation of preliminary data required for the submission of an external, ovarian cancer-relevant grant application (e.g.
Funding Opportunity – American Cancer Society-Institutional Research Grant (IRG)
Description of Program Applications are being solicited for support by the American Cancer Society‐Institutional Research Grant (IRG). These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support. The ACS defines junior faculty as investigators at the rank of assistant […]
Funding Opportunity – Cancer Early Detection and Prevention Initiative
Applications are being solicited for the Vanderbilt-Ingram Cancer Center (VICC) Cancer Early Detection and Prevention Initiative. These funds are designed to provide money to support creating a nurturing environment for basic and clinical research investigations in the field of cancer early detection and prevention (CEDP). The immediate goal of the Initiative is to expand research, […]
Funding Opportunity – American Cancer Society-Institutional Research Grant (IRG)
Description of Program Applications are being solicited for support by the American Cancer Society‐Institutional Research Grant (IRG). These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support. The ACS defines junior faculty as investigators at the rank of assistant […]
Study seeks to ease ‘chemobrain’ for cancer patients
VICC treats first patient in Tennessee with novel cellular immunotherapy
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]
VICC trial putting lung cancer therapy to the test
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]
